QTTB

Q32 BioD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$10.00

-20.9% vs current

Most likely

Base case

45%

Probability

Target price

$5.50

-56.5% vs current

B-

Bear case

30%

Probability

Target price

$2.50

-80.2% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Sentiment is cautious and still mostly monitoring-style. Primary sources support a real mid-2026 clinical catalyst and improved runway, but the March 27, 2026 ATM filing adds a live dilution overhang, and the deterministic prior is negative with only middling evidence quality. The stock looks more like a binary trial-and-financing setup than a clean rerating story today [#10-K-2026-03-10] [#8-K-2026-03-27] [#PR-2026-03-10].

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-15eventSIGNAL-AA Part B 36-week topline data in mid-2026High impact

Q32 says enrollment is complete at 33 patients, dosing is ongoing, and 36-week topline data from SIGNAL-AA Part B are expected in mid-2026; management also says the study is intended to support advancement into pivotal trials if results are supportive [#10-K-2026-03-10] [#PR-2026-03-10].

2026-12-31catalystATM facility leaves dilution overhang despite improved runwayHigh impact

On March 27, 2026 Q32 entered a Cantor Fitzgerald at-the-market program for up to $14.2 million; the company is not obligated to sell, but the facility adds financing optionality and dilution sensitivity after the February 2026 registered direct offering [#8-K-2026-03-27].

2026-12-31catalystRunway and strategic focus improve only if non-dilutive milestones and readout stay on trackHigh impact

The ADX-097 sale provides $12 million in upfront and near-term milestone payments, including $7 million received at signing, $3 million at the 6-month anniversary, and $2 million upon an earlier milestone or end-2026; together with year-end cash and the February financing, management says this supports operations into 2H27/Q4 2027, but that still depends on execution and does not remove longer-term capital needs [#PR-2025-12-01] [#10-K-2026-03-10] [#PR-2026-03-10].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology